"It do prime"
I said in my second reply that perhaps it primes in other ways. Which it does.
In what ways is maraviroc superior to leron other than being approved. I can name a few ways its inferior.
Is there one single way it demonstrates it even possibly carries an advantage .
I would say zero ways.
"In the Phase 1 PICCASSO trial, the combination of pembrolizumab (anti-PD-1) and maraviroc (CCR5 antagonist) showed limited clinical activity, with an Objective Response Rate (ORR) of 5.3% in patients with refractory mismatch repair proficient/microsatellite-stable (pMMR/MSS) metastatic colorectal cancer. While the ORR was low, the combination was found to be feasible and safe, with some patients achieving stable disease"
I said in my second reply that perhaps it primes in other ways. Which it does.
In what ways is maraviroc superior to leron other than being approved. I can name a few ways its inferior.
Is there one single way it demonstrates it even possibly carries an advantage .
I would say zero ways.
"In the Phase 1 PICCASSO trial, the combination of pembrolizumab (anti-PD-1) and maraviroc (CCR5 antagonist) showed limited clinical activity, with an Objective Response Rate (ORR) of 5.3% in patients with refractory mismatch repair proficient/microsatellite-stable (pMMR/MSS) metastatic colorectal cancer. While the ORR was low, the combination was found to be feasible and safe, with some patients achieving stable disease"
5
